Create an Account
  1. Home
  2. Specialty
  3. Retina

Current Management of Retinal Vascular Diseases: Optimizing Treatment Protocol

Current Management of Retinal Vascular Diseases Optimizing Treatment Protocol
Program Information
Take Pre-Test

The live program has concluded.


If you attended, please click on the "Take Post-Test" button to claim your credit. If you did not attend, please stay tuned for the archived version, which will be available soon for on-demand viewing.

Scroll back to top
Details

  • Overview

    A CME activity provided by Evolve Medical Education LLC and distributed with New Retina MD and Retina Today. CONTENT SOURCE This continuing medical education (CME) activity captures content from roundtable discussion held in August 2016 in San Francisco, Ca. TARGET AUDIENCE This certified CME activity is designed for retina specialists and general ophthalmologists involved in the management of patients with retinal disease.Supported through an educational grant from Regeneron Pharmaceuticals.

  • Learning Objectives

    Upon completion of this activity, the participant should be able to:

    • Understand the most recent monotherapy and combination therapy clinical study evidence using available anti-VEGF, steroid, and photodynamic therapies for common retinal diseases, including AMD, RVO, and DME
    • Discuss the outcomes of pivotal studies in AMD, RVO, and DME as well as how study results may differ from real-world dosing methods
    • Develop plans to initiate treatment for conditions such as AMD, RVO, and DME using anti-VEGF agents as well as better understand when to change therapeutic strategies and/or therapeutic classes
    • Evaluate practice flow to determine the most efficient patient experience
    • Develop plans to reduce reimbursement denials

  • Accreditation

    ACCREDITATION STATEMENT

    Evolve Medical Education LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    CREDIT DESIGNATION STATEMENT

    Evolve Medical Education LLC designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Faculty and Disclosures

    DISCLOSURE POLICY
    It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent conflicts of interest relating to the topics of this educational activity. Evolve has full policies in place that will identify and mitigate all conflicts of interest prior to this educational activity.

    FACULTY CREDENTIALS

    Rishi P. Singh, MD, moderator Cole Eye Institute, Cleveland Clinic Cleveland, Ohio

    Jeffrey S. Heier, MD Tufts University/Ophthalmic Consultants of Boston Boston, Massachusetts

    Dante Pieramici, MD California Retina Consultants and Research Foundation Santa Barbara, California

    Jonathan Prenner, MD Rutgers Robert Wood Johnson Medical School New Brunswick, New Jersey

    DISCLOSURE POLICY STATEMENT

    It is the policy of Evolve Medical Education LLC that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent conflict of interests relating to the topics of this educational activity. Evolve Medical Education LLC has full policies in place that will identify and resolve all conflicts of interest prior to this educational activity.

    The following faculty members have the following financial relationships with commercial interests:

    Rishi P. Singh, MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant/Advisory Board/Speaker’s Bureau: Alcon; Genentech; Regeneron Pharmaceuticals; and ThromboGenics NV. Grant/Research Support: Alcon; Genentech; and Regeneron Pharmaceuticals.

    Jeffrey S. Heier, MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant/Advisory Board/Speaker’s Bureau: Acucela; Aerpio; Alcon; Allergan; Bausch + Lomb; Bayer Healthcare Pharmaceuticals; Dutch Ophthalmic; Endo Optiks; Forsight Labs; Genentech; Genzyme/Sanofi; Heidelberg; Kala Rx; Chengdu Kanghong Pharmaceuticals Group; Liquidia; Merz; Nicox; Novartis; Notal Vision Ltd; Ohr Pharmaceuticals; Oraya; QLT; Regeneron Pharmaceuticals; Sequenom; Stealth Peptide; Thrombogenics, NV; and Xcovery. Grant/Research Support: Allergan; Bayer Healthcare Pharmaceuticals; Genentech; Genzyme/Sanofi; GlaxoSmithKline; Lpath; Notal Vision Ltd; Ohr Pharmaceuticals; Ophthotech Corporation; and Regeneron Pharmaceuticals.

    Dante Pieramici, MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant/Advisory Board/Speaker’s Bureau: Allergan; Genentech; and ThromboGenics NV. Grant/Research Support: Alcon; Alimera Sciences; Allergan; Genentech; Ophthotech Corporation; and River Vision.

    Jonathan Prenner, MD, has had a financial agreement or affiliation during the past year with the following commercial interests

    in the form of Consultant/Advisory Board/Speaker’s Bureau: Alcon; and Regeneron Pharmaceuticals. Stock/Shareholder: Ophthotech Corporation; and PanOptica.

    EDITORIAL SUPPORT DISCLOSURE

    Cheryl Cavanaugh, MS, director of operations, Evolve Medical Education LLC; Bryan Bechtel, writer; and David Friess, reviewer, have no financial relationships with commercial interests.

  • Disclaimer

    OFF-LABEL STATEMENT

    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

    DISCLAIMER

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve Medical Education LLC, New Retina MD, Retina Today, or Regeneron Pharmaceuticals.

  • System Requirements

    • Supported Browsers (2 most recent versions):
      • Google Chrome for Windows, Mac OS, iOS, and Android
      • Apple Safari for Mac OS and iOS
      • Mozilla Firefox for Windows, Mac OS, iOS, and Android
      • Microsoft Edge for Windows
    • Recommended Internet Speed: 5Mbps+

  • Publication Dates

    Expiration Date:

1.00 credits
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

LIVE ON REACHMD RADIOBack to live radio
ReachMD Radio

Loading...

00:00
00:00
    Register

    We're glad to see you're enjoying Evolve Medical Education…
    but how about a more personalized experience?

    Register for free